SPYRE THERAPEUTICS, INC. Payments to Acquire Marketable Securities
SPYRE THERAPEUTICS, INC. (SYRE) reported Payments to Acquire Marketable Securities of $19.75 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-07.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2019-05-07
- SPYRE THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2019-03-31 was $19.75M.
- SPYRE THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2018-12-31 was $26.68M, a 1233.95% increase year-over-year.
- SPYRE THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2018-09-30 was $9.25M, a 61.99% decline year-over-year.
- SPYRE THERAPEUTICS, INC. payments to acquire marketable securities for the quarter ending 2017-12-31 was $2.00M.
- SPYRE THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2018 was $62.18M, a 3.02% decline from fiscal 2017.
- SPYRE THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2017 was $64.11M, a 214.44% increase from fiscal 2016.
- SPYRE THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2016 was $20.39M, a 441.42% increase from fiscal 2015.
- SPYRE THERAPEUTICS, INC. payments to acquire marketable securities for fiscal 2015 was $3.77M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2019-03-31 | $19.75M 10-Q · filed 2019-05-07 | $46.43M derived: sum of 2 quarters · filed 2019-05-07 | $55.68M derived: sum of 3 quarters · filed 2019-05-07 | |
| 2018-12-31 | $26.68M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $35.93M derived: sum of 2 quarters · filed 2019-03-07 | $62.18M 10-K · filed 2019-03-07 | |
| 2018-09-30 | $9.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $35.50M 10-Q · filed 2018-11-08 | ||
| 2018-06-30 | $26.25M 10-Q · filed 2018-08-09 | |||
| 2017-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $26.34M derived: sum of 2 quarters · filed 2019-03-07 | $31.34M derived: sum of 3 quarters · filed 2019-03-07 | $64.11M 10-K · filed 2019-03-07 |
| 2017-09-30 | $24.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $29.34M derived: sum of 2 quarters · filed 2018-11-08 | $62.12M 10-Q · filed 2018-11-08 | $62.12M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $37.78M 10-Q · filed 2018-08-09 | $37.78M derived: sum of 3 quarters · filed 2019-03-07 | $55.23M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $32.78M 10-Q · filed 2018-05-08 | $32.78M derived: sum of 2 quarters · filed 2019-03-07 | $50.23M derived: sum of 3 quarters · filed 2019-03-07 | $50.23M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $17.45M derived: sum of 2 quarters · filed 2019-03-07 | $17.45M derived: sum of 3 quarters · filed 2019-03-07 | $20.39M 10-K · filed 2019-03-07 |
| 2016-09-30 | $17.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $17.45M derived: sum of 2 quarters · filed 2017-11-07 | $20.39M 10-Q · filed 2017-11-07 | $20.86M derived: sum of 4 quarters · filed 2018-03-13 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $2.94M 10-Q · filed 2017-08-09 | $3.41M derived: sum of 3 quarters · filed 2018-03-13 | |
| 2016-03-31 | $2.94M 10-Q · filed 2017-05-09 | $3.41M derived: sum of 2 quarters · filed 2018-03-13 | ||
| 2015-12-31 | $470.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $3.77M 10-K · filed 2018-03-13 | ||
| 2015-09-30 | $3.30M 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |